181827-47-4Relevant articles and documents
5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS
-
Paragraph 0234; 0235; 0236; 0237; 0238; 0239, (2018/08/20)
Provided herein are 5,5-fused heteroarylene hepatitis C virus inhibitor compounds, for example, of Formula I, IA, or IB, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.
Preparation method for daclatasvir
-
Paragraph 0080; 0081; 0116; 0117; 0128; 0129, (2017/10/22)
The invention discloses a preparation method for daclatasvir. The preparation method comprises the following steps: in a solvent, performing a cyclization reaction on a compound shown as a formula D10 and ammonium acetate, so as to prepare the daclatasvir shown as a formula I, wherein the cyclization reaction is shown in the description. The preparation method for daclatasvir is low in cost, high in yield, friendly to environment, simple in steps, mild in reaction conditions and suitable for industrialized production.
Novel method for synthesizing dimethyl dicarbamate dihydrochloride compound
-
Paragraph 0058; 0059, (2016/10/10)
The invention relates to a novel method for synthesizing N,N'[[1,1'-biphenyl]4, 4'-diyl bis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-ethylmethyl)-2-oxo-2,1-ethanediyl]]] dimethyl dicarbamate dihydrochloride. According to the novel method d